• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

Jan 22nd $7 bump completed eliminated over the last couple days.


<



Most likely the down turn today was mostly the rhetoric from Trump and drug price control. Certainly the market downturn as well as the Amazon, Berkshire, PM healthcare plan weights in but this will pass and the stock will tick upward.
 




Similar threads

Replies
25
Views
9K
Allergan
anonymous